Clinical trial · Interventional
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
HOPE Program: Quality of Life Enhancement and Survivorship Care
NCT01126346CI-TRIAL-00033599HOPEcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: An orientation and patient education program and telephone counseling may help improve the quality of life in patients with peritoneal surface malignancies. PURPOSE: This clinical trial studies quality of life and survivorship care in patients undergoing surgery and chemotherapy for peritoneal surface malignancies.
Conditions
Conditions (16)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Malignant Mesothelioma | Malignant Mesothelioma | CURATED_BROADER | 0.78 |
| Carcinoma of the Appendix | Appendix Carcinoma | ALIAS | 0.90 |
| Ovarian Sarcoma | Ovarian Sarcoma | ONTOLOGY_EXACT | 0.98 |
| Ovarian Stromal Cancer | Malignant Ovarian Epithelial Tumor | ALIAS | 0.90 |
| Pseudomyxoma Peritonei | Pseudomyxoma Peritonei | ONTOLOGY_EXACT | 0.98 |
| Recurrent Colon Cancer | Malignant Colon Neoplasm | CURATED_BROADER | 0.78 |
| Recurrent Malignant Mesothelioma | Malignant Mesothelioma | CURATED_BROADER | 0.78 |
| Recurrent Ovarian Epithelial Cancer | Ovarian Carcinoma | CURATED_BROADER | 0.78 |
| Recurrent Ovarian Germ Cell Tumor | Ovarian Germ Cell Tumor |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Consultation with Survivorship Navigator | Behavioral | — | UNRESOLVED |
| HIPEC Orientation | Behavioral | — | UNRESOLVED |
| Questionnaires | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm I
- description
- Patients and their caregiver(s) receive a hyperthermic intraperitoneal chemotherapy (HIPEC) orientation with a Survivorship Navigator (SN) over 90 minutes following their initial surgical consult. Patients then receive telephone calls over 20-30 minutes from the SN once weekly for 3 weeks prior to HIPEC. After HIPEC, patients meet with the SN for 20-30 minutes to discuss adjustments and adaptation to the surgery and hospitalization 3-4 days post-HIPEC, biweekly for two weeks and weekly thereafter until hospital discharge. After hospital discharge, patients receive telephone calls from the SN twice monthly for 1 month.
- interventionNames
- Behavioral: HIPEC Orientation
- Behavioral: Consultation with Survivorship Navigator
- Other: Questionnaires
Primary outcomes (1)
- measure
- Assess feasibility of instituting an orientation program, brief follow up care and phone calls in this patient population
- timeFrame
- Baseline to 3 months post discharge
- description
- Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion * Patients who undergo CS and HIPEC for peritoneal surface malignancy
References
Publications (0)
Data not yet available
No reference posted for this study.